Drugs / [18F]PI-2620
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05651516 | Sep 2023 → Jun 2026 | substance-related disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT03510572 | Jun 2018 → Jul 2019 | Alzheimer disease, Parkinson disease, frontotemporal dementia | Asan Medical Center | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05187546 | Mar 2022 → Feb 2024 | progressive supranuclear palsy | Life Molecular Imaging GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05337774 | Jun 2021 → Apr 2022 | traumatic brain injury | Lantheus Biosciences Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04715750 | Nov 2020 → Oct 2022 | Alzheimer disease, progressive supranuclear palsy | Life Molecular Imaging GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03903211 | Apr 2019 → Feb 2021 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Jae Seung Kim | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05641688 | Dec 2022 → Jun 2027 expected | Alzheimer disease | Lantheus Biosciences Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[18F\]PI-2620 | “\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being...” NCT04715750 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission computed tomography radioligand” NCT03510572 ↗ |
| Route | Intravenous | “single IV injection” NCT03510572 ↗ |